{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:10:10Z","timestamp":1792091410188,"version":"4.4.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40264-020-00965-w","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T21:03:30Z","timestamp":1592859810000},"page":"699-709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["The Impact of the COVID-19 \u201cInfodemic\u201d on Drug-Utilization Behaviors: Implications for Pharmacovigilance"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-8486","authenticated-orcid":false,"given":"Marco","family":"Tuccori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Convertino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Cappello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Valdiserra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Focosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Blandizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"key":"965_CR1","doi-asserted-by":"crossref","unstructured":"Siordia JA. Epidemiology and clinical features of COVID-19: a review of current literature. J Clin Virol [Internet]. 2020;127:104357. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32305884.","DOI":"10.1016\/j.jcv.2020.104357"},{"key":"965_CR2","doi-asserted-by":"crossref","unstructured":"Zarocostas J. How to fight an infodemic. Lancet (London, England). NLM (Medline); 2020;395:676.","DOI":"10.1016\/S0140-6736(20)30461-X"},{"key":"965_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.4014\/jmb.2003.03011","volume":"30","author":"D-G Ahn","year":"2020","unstructured":"Ahn D-G, Shin H-J, Kim M-H, Lee S, Kim H-S, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. Korea (South). 2020;30:313\u201324.","journal-title":"J Microbiol Biotechnol. Korea (South)"},{"key":"965_CR4","doi-asserted-by":"crossref","unstructured":"Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 Infe. J Am Heart Assoc. England; 2020;9:e016219.","DOI":"10.1161\/JAHA.120.016219"},{"key":"965_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/qjmed\/hcp052","volume":"102","author":"JK Aronson","year":"2009","unstructured":"Aronson JK. Medication errors: what they are, how they happen, and how to avoid them. QJM. England. 2009;102:513\u201321.","journal-title":"QJM. England"},{"key":"965_CR6","unstructured":"Coronavirus: come si \u00e8 arrivati alla sperimentazione della Clorochina\u2014ISS [Internet]. [cited 2020 Apr 7]. https:\/\/www.iss.it\/coronavirus\/-\/asset_publisher\/1SRKHcCJJQ7E\/content\/id\/5269460."},{"key":"965_CR7","doi-asserted-by":"crossref","unstructured":"Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today\u2019s diseases? Lancet Infect. Dis. Lancet Publishing Group; 2003. p. 722\u20137.","DOI":"10.1016\/S1473-3099(03)00806-5"},{"key":"965_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","volume":"323","author":"E Keyaerts","year":"2004","unstructured":"Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004;323:264\u20138.","journal-title":"Biochem Biophys Res Commun."},{"key":"965_CR9","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1128\/AAC.01509-08","volume":"53","author":"E Keyaerts","year":"2009","unstructured":"Keyaerts E, Li S, Vijgen L, Rysman E, Verbeeck J, Van Ranst M, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009;53:3416\u201321.","journal-title":"Antimicrob Agents Chemother."},{"key":"965_CR10","doi-asserted-by":"crossref","unstructured":"Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. Elsevier BV; 2020;105938.","DOI":"10.1016\/j.ijantimicag.2020.105938"},{"key":"965_CR11","unstructured":"Shanping J. A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19) (ChiCTR2000029542) [Internet]. Chinese Clin. Trial Regist. 2020 [cited 2020 Apr 27]. http:\/\/www.chictr.org.cn\/showprojen.aspx?proj=48968."},{"key":"965_CR12","unstructured":"Grady D, Thomas K. With Minimal Evidence, Trump Asks F.D.A. to Study Malaria Drugs for Coronavirus [Internet]. New York Times. [cited 2020 Apr 27]. https:\/\/www.nytimes.com\/2020\/03\/19\/health\/coronavirus-drugs-chloroquine.html."},{"key":"965_CR13","doi-asserted-by":"crossref","unstructured":"Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. Netherlands; 2020;105949.","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"965_CR14","unstructured":"Wong, Julia C. Hydroxychloroquine: how an unproven drug became Trump\u2019s coronavirus \u201cmiracle cure\u201d. The Guardian. Guard [Internet]. https:\/\/www.theguardian.com\/world\/2020\/apr\/06\/hydroxychloroquine-trump-coronavirus-drug."},{"key":"965_CR15","doi-asserted-by":"publisher","first-page":"m1844","DOI":"10.1136\/bmj.m1844","volume":"2019","author":"M Mah\u00e9vas","year":"2020","unstructured":"Mah\u00e9vas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. Bmj. 2020;2019:m1844.","journal-title":"Bmj."},{"key":"965_CR16","unstructured":"Beaumont P, Ratcliffe R. Chloroquine: Trump\u2019s misleading claims spark hoarding and overdoses [Internet]. Guard. [cited 2020 Apr 27]. https:\/\/www.theguardian.com\/science\/2020\/mar\/25\/can-chloroquine-really-help-treat-coronavirus-patients."},{"key":"965_CR17","unstructured":"Boseley S. Vital drug for people with lupus running out after unproven Covid-19 link [Internet]. Guard. 2020 [cited 2020 Apr 27]. https:\/\/www.theguardian.com\/world\/2020\/mar\/27\/vital-drug-people-lupus-coronavirus-covid-19-link-hydroxychloroquine."},{"key":"965_CR18","unstructured":"[no author listed]. COVID-19: nuove indicazioni AIFA per gestire il rischio di carenza di idrossiclorochina [Internet]. AIFA Off. website. [cited 2020 May 5]. https:\/\/www.aifa.gov.it\/-\/covid-19-nuove-indicazioni-aifa-per-gestire-il-rischio-di-carenza-di-idrossiclorochina."},{"key":"965_CR19","unstructured":"Sheperd K. A man thought aquarium cleaner with the same name as the anti-viral drug chloroquine would prevent coronavirus. It killed him. [Internet]. Washington Post. [cited 2020 Apr 27]. https:\/\/www.washingtonpost.com\/nation\/2020\/03\/24\/coronavirus-chloroquine-poisoning-death\/."},{"key":"965_CR20","unstructured":"McCall R. Some Swedish Hospitals have stopped using chloroquine to treat COVID-19 after reports of severe SIDE effects [Internet]. Newsweek. [cited 2020 Apr 27]. https:\/\/www.newsweek.com\/swedish-hospitals-chloroquine-covid-19-side-effects-1496368."},{"key":"965_CR21","doi-asserted-by":"crossref","unstructured":"Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet (London, England) [Internet]. 2020;6736:31290. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32450107.","DOI":"10.1016\/S0140-6736(20)31180-6"},{"key":"965_CR22","unstructured":"O\u2019Riordan M. Lancet COVID-19 Hydroxychloroquine Study Faces \u2018Data Integrity\u2019 Questions [Internet]. tctmd.com. 2020 [cited 2020 Jun 3]. https:\/\/www.tctmd.com\/news\/lancet-covid-19-hydroxychloroquine-study-faces-data-integrity-questions."},{"key":"965_CR23","doi-asserted-by":"crossref","unstructured":"Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet (London, England) [Internet]. Elsevier Ltd; 2020;6736:31324. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32450107.","DOI":"10.1016\/S0140-6736(20)31180-6"},{"key":"965_CR24","doi-asserted-by":"crossref","unstructured":"Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments [Internet]. Science (80-.). [cited 2020 Apr 28]. https:\/\/www.sciencemag.org\/news\/2020\/03\/who-launches-global-megatrial-four-most-promising-coronavirus-treatments.","DOI":"10.1126\/science.abb8497"},{"key":"965_CR25","doi-asserted-by":"crossref","unstructured":"Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;3\u20137.","DOI":"10.1016\/j.jcrc.2020.03.005"},{"key":"965_CR26","unstructured":"[no author listed]. COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes [Internet]. Eurpean Med. Agency Off. Webpage. [cited 2020 Apr 28]. https:\/\/www.ema.europa.eu\/en\/news\/covid-19-chloroquine-hydroxychloroquine-only-be-used-clinical-trials-emergency-use-programmes."},{"key":"965_CR27","unstructured":"[no author listed]. Fact sheet for patients and parents\/caregivers emergency use authorization (EUA) of hydroxychloroquine sulfate for treatment of Covid-19 in certain hospitalized patients [Internet]. Food Drug Adm. Off. Webpage. [cited 2020 Apr 28]. https:\/\/www.fda.gov\/media\/136538\/download."},{"key":"965_CR28","unstructured":"Comunicazione AIFA sull\u2019utilizzo di Clorochina e Idrossiclorochina nella terapia dei pazienti affetti da COVID-19\u2014Informazioni di sicurezza [Internet]. [cited 2020 Apr 2]. https:\/\/www.aifa.gov.it\/-\/comunicazione-aifa-sull-utilizzo-di-clorochina-e-idrossiclorochina-nella-terapia-dei-pazienti-affetti-da-covid-19-informazioni-di-sicurezza."},{"key":"965_CR29","unstructured":"[no author listed]. FDA Letter to Stakeholders: Do Not Use Chloroquine Phosphate Intended for Fish as Treatment for COVID-19 in Humans [Internet]. Food Drug Adm. Off. Website. [cited 2020 Apr 28]. https:\/\/www.fda.gov\/animal-veterinary\/product-safety-information\/fda-letter-stakeholders-do-not-use-chloroquine-phosphate-intended-fish-treatment-covid-19-humans."},{"key":"965_CR30","unstructured":"[no author listed]. FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems [Internet]. FDA Off. Website. [cited 2020 May 5]. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or."},{"key":"965_CR31","unstructured":"Cuppini L. Aifa: Clorochina non approvata per prevenire infezione da Sars-CoV-2 [Internet]. Corr. della Sera. [cited 2020 Apr 28]. https:\/\/www.corriere.it\/salute\/malattie_infettive\/20_aprile_01\/aifa-clorochina-non-approvata-prevenire-infezione-sars-cov-2-53179152-7370-11ea-bc49-338bb9c7b205.shtml."},{"key":"965_CR32","unstructured":"[no author listed]. Q&A\u202f: Hydroxychloroquine and COVID-19 [Internet]. World Heal. Organ. 2020 [cited 2020 Jun 3]. https:\/\/www.who.int\/news-room\/q-a-detail\/q-a-hydroxychloroquine-and-covid-19."},{"key":"965_CR33","unstructured":"[no author listed]. COVID-19. Le motivazioni della decisione AIFA sull\u2019uso di idrossiclorochina e clorochina [Internet]. AIFA Off. website. 2020 [cited 2020 Jun 8]. https:\/\/www.aifa.gov.it\/-\/covid-19-le-motivazioni-della-decisione-aifa-sull-uso-di-idrossiclorochina-e-clorochina."},{"key":"965_CR34","unstructured":"Park A. WHO Resumes Study of Hydroxychloroquine for Treating COVID-19 [Internet]. Time. 2020 [cited 2020 Jun 8]. https:\/\/time.com\/5847664\/who-hydroxychloroquine-covid-19\/."},{"key":"965_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.bbrc.2020.02.071","volume":"525","author":"Y Chen","year":"2020","unstructured":"Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020;525:135\u201340.","journal-title":"Biochem Biophys Res Commun"},{"key":"965_CR36","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605\u201310.","journal-title":"Circulation."},{"key":"965_CR37","doi-asserted-by":"crossref","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med [Internet]. Elsevier Ltd; 2020;8:e21. http:\/\/dx.doi.org\/10.1016\/S2213-2600(20)30116-8.","DOI":"10.1016\/S2213-2600(20)30116-8"},{"key":"965_CR38","unstructured":"Sun ML, Yang JM, Sun YP, Su GH. [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi [Internet]. 2020 [cited 2020 Apr 21];43:219\u201322. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32061198."},{"key":"965_CR39","doi-asserted-by":"crossref","unstructured":"Lippi G, Mattiuzzi C, Sanchis-Gomar F, Henry BM. Clinical and demographic characteristics of patients dying from COVID-19 in Italy versus China. J Med Virol. United States; 2020.","DOI":"10.1002\/jmv.25860"},{"key":"965_CR40","doi-asserted-by":"crossref","unstructured":"Cheng H, Wang Y, Wang G-Q. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. Wiley; 2020.","DOI":"10.1002\/jmv.25785"},{"key":"965_CR41","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112\u20136.","journal-title":"Nature."},{"key":"965_CR42","doi-asserted-by":"crossref","unstructured":"Focosi D, Tuccori M, Maggi F. ACE Inhibitors and AT1R Blockers for COVID-2019: Friends or Foes\u202f? Preprints [Internet]. 2020. https:\/\/www.preprints.org\/manuscript\/202004.0151\/v2.","DOI":"10.20944\/preprints202004.0151.v2"},{"key":"965_CR43","unstructured":"Kekatos, Mary; Blanchard S. High blood pressure and diabetes medication taken by 13 million Americans could raise the risk of serious coronavirus symptoms, scientists say. Dly Mail [Internet]. https:\/\/www.dailymail.co.uk\/health\/article-8109453\/High-blood-pressure-diabetes-drugs-raise-risk-coronavirus-symptoms.html."},{"key":"965_CR44","unstructured":"Puente D. Ibuprofene e coronavirus. Il falso testo Whatsapp associato al chirurgo Pascale del Galeazzi di Milano. Parte la denuncia [Internet]. Open Online. https:\/\/www.open.online\/2020\/03\/17\/ibuprofene-e-coronavirus-il-falso-test-whatsapp-associato-al-chirurgo-pascale-del-galeazzi-di-milano-parte-la-denuncia\/."},{"key":"965_CR45","unstructured":"Societ\u00e0 Italiana dell\u2019Ipertensione Arteriosa. Farmaci antiipertensivi e rischio di COVID-19. Il comunicato della SIIA [Internet]. 2020. https:\/\/siia.it\/notizie-siia\/farmaci-antiipertensivi-e-rischio-di-covid-19-il-comunicato-della-siia\/."},{"key":"965_CR46","unstructured":"Societ\u00e0 Italiana di Farmacologia. Documento Informativo della Societ\u00e0 Italiana di Farmacologia\u2014Uso di Ace-Inibitori\/Sartani ed infezione da COVID-19 [Internet]. 2020. https:\/\/www.sifweb.org\/documenti\/document_2020-03-13_documento-informativo-della-societa-italiana-di-farmacologia-uso-di-ace-inibitori-sartani-ed-infezione-da-covid-19."},{"key":"965_CR47","unstructured":"Euroepan Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers [Internet]. 2020. https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang."},{"key":"965_CR48","unstructured":"European Medicines Agency. EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic [Internet]. 2020. https:\/\/www.ema.europa.eu\/en\/news\/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic."},{"key":"965_CR49","unstructured":"Di Castelnuovo A. ACE inhibitors, angiotensin II type-I receptor blockers and severity of COVID-19 (CODIV-ACE) (NCT04318418) [Internet]. [cited 2020 Apr 23]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04318418."},{"key":"965_CR50","unstructured":"Ludwig M. Stopping ACE-inhibitors in COVID-19 (ACEI-COVID)(NCT04353596) [Internet]. 2020 [cited 2020 Apr 23]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04353596."},{"key":"965_CR51","doi-asserted-by":"crossref","unstructured":"Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. Massachusetts Medical Society; 2020.","DOI":"10.1056\/NEJMoa2007621"},{"key":"965_CR52","doi-asserted-by":"crossref","unstructured":"Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of covid-19. N Engl J Med. Massachusetts Medical Society; 2020.","DOI":"10.1056\/NEJMoa2008975"},{"key":"965_CR53","doi-asserted-by":"crossref","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin\u2013angiotensin\u2013aldosterone system blockers and the risk of covid-19. N Engl J Med. Massachusetts Medical Society; 2020.","DOI":"10.1056\/NEJMoa2006923"},{"key":"965_CR54","unstructured":"Food and Drug Administration. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19 | FDA [Internet]. [cited 2020 Apr 2]. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19."},{"key":"965_CR55","first-page":"97","volume":"131","author":"W Qiao","year":"2015","unstructured":"Qiao W, Wang C, Chen B, Zhang F, Liu Y, Lu Q, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiol. S. Karger AG. 2015;131:97\u2013106.","journal-title":"Cardiol. S. Karger AG"},{"key":"965_CR56","unstructured":"Willsher K. Anti-inflammatories may aggravate Covid-19, France advises | World news | The Guardian [Internet]. 2020 [cited 2020 Apr 1]. https:\/\/www.theguardian.com\/world\/2020\/mar\/14\/anti-inflammatory-drugs-may-aggravate-coronavirus-infection."},{"key":"965_CR57","doi-asserted-by":"crossref","unstructured":"Day M. Covid-19: European drugs agency to review safety of ibuprofen. BMJ [Internet]. 2020;368:m1168. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32205306.","DOI":"10.1136\/bmj.m1168"},{"key":"965_CR58","unstructured":"Kolata G. Is ibuprofen really risky for coronavirus patients? [Internet]. New York Times. [cited 2020 May 5]. https:\/\/www.nytimes.com\/2020\/03\/17\/health\/coronavirus-ibuprofen.html."},{"key":"965_CR59","unstructured":"Schraer R, Goodman J, Coleman A. Coronavirus and ibuprofen: Separating fact from fiction [Internet]. BBC News Website. [cited 2020 May 5]. https:\/\/www.bbc.com\/news\/51929628."},{"key":"965_CR60","unstructured":"Health Agencies: No Evidence Ibuprofen Worsens Coronavirus\u2014The New York Times."},{"key":"965_CR61","unstructured":"European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19 | European Medicines Agency. Eur Med Agency [Internet]. 2020;31:18\u20139. https:\/\/www.ema.europa.eu\/en\/news\/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19."},{"key":"965_CR62","unstructured":"[no author listed]. Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019 (COVID-19) Infections: a Case-control Study (NCT04383899) [Internet]. clinicaltrials.gov. 2020 [cited 2020 Jun 3]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04383899."},{"key":"965_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2040206618764483","volume":"26","author":"PC Jordan","year":"2018","unstructured":"Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother. 2018;26:1\u201329.","journal-title":"Antivir Chem Chemother."},{"key":"965_CR64","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","volume":"153","author":"L Delang","year":"2018","unstructured":"Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018;153:85\u201394.","journal-title":"Antiviral Res."},{"key":"965_CR65","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14:58\u201360.","journal-title":"Drug Discov Ther."},{"key":"965_CR66","doi-asserted-by":"crossref","unstructured":"Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020;4\u201310.","DOI":"10.1016\/j.eng.2020.03.007"},{"key":"965_CR67","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir\u2013ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;1787\u201399."},{"key":"965_CR68","unstructured":"McCurry J. Japanese flu drug \u201cclearly effective\u201d in treating coronavirus, says China [Internet]. Guard. 2020 [cited 2020 Apr 27]. https:\/\/www.theguardian.com\/world\/2020\/mar\/18\/japanese-flu-drug-clearly-effective-in-treating-coronavirus-says-china."},{"key":"965_CR69","unstructured":"D\u2019Aria I. Coronavirus, la speranza dell\u2019antivirale Avigan e il video su Facebook. I dubbi dell\u2019Aifa e la sperimentazione in Veneto [Internet]. La Repubb. 2020 [cited 2020 Apr 27]. https:\/\/www.repubblica.it\/salute\/medicina-e-ricerca\/2020\/03\/22\/news\/coronavirus_a_tokio_la_speranza_di_un_anti-virale_che_funziona_da_domani_sperimentazione_anche_in_italia-251983590\/."},{"key":"965_CR70","unstructured":"Fujifilm d\u00e9colle \u00e0 Tokyo, l\u2019un de ses m\u00e9dicaments efficace contre le Covid-19 selon P\u00e9kin\u2014Le Figaro [Internet]. [cited 2020 Apr 20]. https:\/\/www.lefigaro.fr\/flash-eco\/fujifilm-decolle-a-tokyo-l-un-de-ses-medicaments-efficace-contre-le-covid-19-selon-pekin-20200318."},{"key":"965_CR71","unstructured":"D\u2019Aria I. Covid-19: Speranza, \u201cAifa procede su sperimentazione Avigan\u201d [Internet]. La Repubb. 2020 [cited 2020 Apr 27]. https:\/\/www.repubblica.it\/salute\/medicina-e-ricerca\/2020\/03\/23\/news\/covid-19_speranza_aifa_procede_su_sperimentazione_avigan_-252090636\/."},{"key":"965_CR72","unstructured":"[no author listed]. La bufala del farmaco Arbidol [Internet]. Corr. della Sera. 2020 [cited 2020 Apr 27]. https:\/\/video.corriere.it\/bufala-farmaco-arbidol\/277e5b16-6c3b-11ea-8403-94d97cb6fb9f."},{"key":"965_CR73","unstructured":"[no author listed]. SPAIN\u202f: 58% OF ILLEGAL CORONAVIRUS MEDICINE AND MASK SUPPLIES CHANNELED THROUGH SOCIAL MEDIA [Internet]. Int. Inst. Res. Against Counterfeit Med. Website. [cited 2020 May 5]. https:\/\/www.iracm.com\/en\/2020\/04\/spain-58-illegal-coronavirus-medicine-mask-supplies-channeled-social-media\/."},{"key":"965_CR74","unstructured":"Kuchler, Hanna; Inagaki, Kana; Neville S. The global hunt for a coronavirus drug [Internet]. Finacial Times. 2020 [cited 2020 Apr 27]. https:\/\/www.ft.com\/content\/91bd081e-6e7b-11ea-9bca-bf503995cd6f."},{"key":"965_CR75","doi-asserted-by":"crossref","unstructured":"Jin Z, Tucker K, Lin X, Kao CC, Shaw K, Tan H, et al. Biochemical evaluation of the inhibition properties of favipiravir and 2=-C-methyl-cytidine triphosphates against human and mouse norovirus RNA polymerases. Antimicrob Agents Chemother. American Society for Microbiology; 2015;59:7504\u201316.","DOI":"10.1128\/AAC.01391-15"},{"key":"965_CR76","doi-asserted-by":"crossref","unstructured":"Nagata T, Lefor AK, Hasegawa M, Ishii M. Favipiravir: A New Medication for the Ebola Virus Disease Pandemic. Disaster Med Public Health Prep. Cambridge University Press; 2015;9:79\u201381.","DOI":"10.1017\/dmp.2014.151"},{"key":"965_CR77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","volume":"6","author":"V Pilkington","year":"2020","unstructured":"Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir\u2014a potential treatment in the COVID-19 pandemic? J Virus Erad. 2020;6:45\u201351.","journal-title":"J Virus Erad"},{"key":"965_CR78","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1073\/pnas.1811345115","volume":"115","author":"DH Goldhill","year":"2018","unstructured":"Goldhill DH, Te Velthuis AJW, Fletcher RA, Langat P, Zambon M, Lackenby A, et al. The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci USA. 2018;115:11613\u20138.","journal-title":"Proc Natl Acad Sci USA."},{"key":"965_CR79","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1093\/gbe\/evx138","volume":"9","author":"L Ormond","year":"2017","unstructured":"Ormond L, Liu P, Matuszewski S, Renzette N, Bank C, Zeldovich K, et al. The combined effect of oseltamivir and favipiravir on influenza a virus evolution. Genome Biol Evol. 2017;9:1913\u201324.","journal-title":"Genome Biol Evol."},{"key":"965_CR80","unstructured":"[no author listed]. Fujifilm announces the start of a phase III clinical trial of influenza antiviral drug \u201cAvigan Tablet\u201d on COVID-19 and commits to increasing production [Internet]. Fujifilm Off. website. 2020 [cited 2020 Apr 27]. https:\/\/www.fujifilm.com\/jp\/en\/news\/hq\/3211."},{"key":"965_CR81","unstructured":"Favipiravir: aggiornamento della valutazione della CTS [Internet]. [cited 2020 Apr 20]. https:\/\/www.aifa.gov.it\/-\/favipiravir-aggiornamento-della-valutazione-della-cts."},{"key":"965_CR82","unstructured":"AIFA precisa, uso favipiravir per COVID-19 non autorizzato in Europa e USA, scarse evidenze scientifiche sull\u2019efficacia [Internet]. [cited 2020 Apr 20]. https:\/\/www.aifa.gov.it\/-\/aifa-precisa-uso-favipiravir-per-covid-19-non-autorizzato-in-europa-e-usa-scarse-evidenze-scientifiche-sull-efficacia."},{"key":"965_CR83","unstructured":"Rizzardini G. Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19\u2014NCT04336904 [Internet]. clincialtrial.gov. 2020 [cited 2020 Apr 27]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04336904?term\u2009=\u2009favipiravir&cond\u2009=\u2009Covid-19&draw=4&rank=1."},{"key":"965_CR84","doi-asserted-by":"crossref","unstructured":"Haviernik J, \u0160tef\u00e1nik M, Fojt\u00edkov\u00e1 M, Kali S, Tordo N, Rudolf I, et al. Arbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses. MDPI AG; 2018;10.","DOI":"10.20944\/preprints201802.0134.v1"},{"key":"965_CR85","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00705-007-0974-5","volume":"152","author":"L Shi","year":"2007","unstructured":"Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol. 2007;152:1447\u201355.","journal-title":"Arch Virol"},{"key":"965_CR86","first-page":"56","volume":"91","author":"NY Pshenichnaya","year":"2019","unstructured":"Pshenichnaya NY, Bulgakova VA, Lvov NI, Poromov AA, Selkova EP, Grekova AI, et al. Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR). Ter Arkh. Consilium Medikum. 2019;91:56\u201363.","journal-title":"Ter Arkh. Consilium Medikum"},{"key":"965_CR87","doi-asserted-by":"crossref","unstructured":"Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. W.B. Saunders Ltd; 2020.","DOI":"10.1016\/j.jinf.2020.03.002"},{"key":"965_CR88","doi-asserted-by":"crossref","unstructured":"Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. Elsevier B.V.; 2020.","DOI":"10.1016\/j.cmi.2020.04.026"},{"key":"965_CR89","unstructured":"Puente, David; Pill J. Il complottone del farmaco Arbidol (o Abidol) contro il coronavirus non venduto in Italia. Fate attenzione! [Internet]. Open Online. 2020 [cited 2020 Apr 27]. https:\/\/www.open.online\/2020\/03\/17\/il-complottone-del-farmaco-arbidol-o-abidol-contro-il-coronavirus-non-venduto-in-italia-fate-attenzione\/."},{"key":"965_CR90","unstructured":"[no author listed]. Coronavirus, la fake news sul farmaco russo. Burioni: Non serve a niente, basta con le bufale [Internet]. Messagg. [cited 2020 Apr 27]. https:\/\/www.ilmessaggero.it\/salute\/medicina\/coronavirus_farmaco_russia_arbidol_fake_news_17_marzo_2020-5116727.html."},{"key":"965_CR91","unstructured":"Corrado P. \u201cArbidol, il farmaco russo che salva dal Coronavirus\u201d. Ma \u00e8 una bufala [Internet]. Il Secolo d\u2019Italia. 2020 [cited 2020 Apr 27]. https:\/\/www.secoloditalia.it\/2020\/03\/arbidol-il-farmaco-russo-che-salva-dal-coronavirus-ma-e-una-bufala-video\/."},{"key":"965_CR92","unstructured":"Dunn W. How coronavirus is worsening the UK\u2019s problem with unlicensed drugs [Internet]. NewStatesman website. [cited 2020 May 5]. https:\/\/www.newstatesman.com\/science-tech\/coronavirus\/2020\/03\/what-arbidol-russian-coronavirus-cure-being-sold-ebay."},{"key":"965_CR93","unstructured":"Listed] [no author. COVID-19: attenzione ai medicinali falsificati provenienti da siti web non registrati [Internet]. AIFA Off. website. 2020 [cited 2020 Apr 27]. https:\/\/www.aifa.gov.it\/web\/guest\/-\/covid-19-attenzione-ai-medicinali-falsificati-provenienti-da-siti-web-non-registrati."},{"key":"965_CR94","unstructured":"Valvo L, Bartolomei M, Gaudiano MC, Sestili I, Manna L, Antoniella E, et al. Indicazioni relative ai rischi di acquisto online di farmaci per la prevenzione e terapia dell\u2019infezione COVID-19 e alla diffusione sui social network di informazioni false sulle terapie [Internet]. 2020 [cited 2020 Apr 27]. https:\/\/www.epicentro.iss.it\/coronavirus\/pdf\/rapporto-covid-19-15-2020.pdf."},{"key":"965_CR95","unstructured":"Di Grazia S. Esiste un farmaco russo che cura la Covid-19? [Internet]. Fed. Ital. dei Medici Chir. e Odontoiatr. Off. Website. 2020 [cited 2020 Apr 27]. https:\/\/dottoremaeveroche.it\/esiste-un-farmaco-russo-che-cura-la-covid-19\/."},{"key":"965_CR96","doi-asserted-by":"crossref","unstructured":"Caddy S. Developing a vaccine for covid-19. BMJ. England; 2020. p. m1790.","DOI":"10.1136\/bmj.m1790"},{"key":"965_CR97","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","volume":"26","author":"KG Andersen","year":"2020","unstructured":"Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26:450\u20132.","journal-title":"Nat Med."},{"key":"965_CR98","doi-asserted-by":"crossref","unstructured":"Orso D, Federici N, Copetti R, Vetrugno L, Bove T. Infodemic and the spread of fake news in the COVID-19-era. Eur J Emerg Med. England; 2020.","DOI":"10.1097\/MEJ.0000000000000713"},{"key":"965_CR99","doi-asserted-by":"crossref","unstructured":"Gnegel G, Hauk C, Neci R, Mutombo G, Nyaah F, Wistuba D, et al. Identification of Falsified Chloroquine Tablets in Africa at the Time of the COVID-19 Pandemic. Am J Trop Med Hyg [Internet]. 2020; http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32400349.","DOI":"10.4269\/ajtmh.20-0363"},{"key":"965_CR100","unstructured":"[no author listed]. DH-BIO Statement on human rights considerations relevant to the COVID-19 pandemic [Internet]. 2020. https:\/\/rm.coe.int\/inf-2020-2-statement-covid19-e\/16809e2785."},{"key":"965_CR101","unstructured":"[no author listed]. Position of the European Network of Research Ethics Committees (EUREC) on the Responsibility of Research Ethics Committees during the COVID-19 Pandemic. 2020."},{"key":"965_CR102","unstructured":"[no author listed]. Guidance on the Management of clinical trials during the COVID-19 (corona virus) pandemic. 2020."},{"key":"965_CR103","doi-asserted-by":"crossref","unstructured":"Glasziou PP, Sanders S, Hoffmann T. Waste in covid-19 research. BMJ [Internet]. 2020;369:m1847. http:\/\/doi.org\/10.1136\/bmj.m1847.","DOI":"10.1136\/bmj.m1847"},{"key":"965_CR104","doi-asserted-by":"publisher","first-page":"496","DOI":"10.15585\/mmwr.mm6916e1","volume":"69","author":"A Chang","year":"2020","unstructured":"Chang A, Schnall AH, Law R, Bronstein AC, Marraffa JM, Spiller HA, et al. Cleaning and disinfectant chemical exposures and temporal associations with COVID-19\u2014National Poison Data System, United States, January 1, 2020\u2013March 31, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:496\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"965_CR105","doi-asserted-by":"publisher","unstructured":"Caster O, Dietrich J, K\u00fcrzinger ML, Lerch M, Maskell S, Nor\u00e9n GN, et al. Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project. Drug Saf [Internet]. Springer International Publishing; 2018;41:1355\u201369. https:\/\/doi.org\/10.1007\/s40264-018-0699-2.","DOI":"10.1007\/s40264-018-0699-2"},{"key":"965_CR106","doi-asserted-by":"crossref","unstructured":"Convertino I, Ferraro S, Blandizzi C, Tuccori M. The usefulness of listening social media for pharmacovigilance purposes: a systematic review. Expert Opin Drug Saf [Internet]. Taylor and Francis Ltd; 2018 [cited 2020 Apr 1];17:1081\u201393. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30285501.","DOI":"10.1080\/14740338.2018.1531847"},{"key":"965_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyg.2016.01617","volume":"7","author":"R V\u00e1gv\u00f6lgyi","year":"2016","unstructured":"V\u00e1gv\u00f6lgyi R, Coldea A, Dresler T, Schrader J, Nuerk HC. A review about functional illiteracy: Definition, cognitive, linguistic, and numerical aspects. Front Psychol. 2016;7:1\u201313.","journal-title":"Front Psychol."},{"key":"965_CR108","doi-asserted-by":"crossref","unstructured":"Pierri F, Piccardi C, Ceri S. Topology comparison of Twitter diffusion networks effectively reveals misleading information. Sci Rep [Internet]. Springer US; 2020;10:1\u20139. http:\/\/dx.doi.org\/10.1038\/s41598-020-58166-5.","DOI":"10.1038\/s41598-020-58166-5"},{"key":"965_CR109","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/0163278704267037","volume":"27","author":"SS Kim","year":"2004","unstructured":"Kim SS, Kaplowitz S, Johnston MV. The effects of physician empathy on patient satisfaction and compliance. Eval Health Prof. 2004;27:237\u201351.","journal-title":"Eval Health Prof"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00965-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T19:16:38Z","timestamp":1696274198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00965-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":109,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["965"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00965-w","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,22]]},"assertion":[{"value":"22 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marco Tuccori, Irma Convertino, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Daniele Focosi, and Corrado Blandizzi have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors agree with the publication of this paper.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material (Data Transparency)"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability (Software Application or Custom Code)"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}